{
    "medicine_id": "b1aac8c188c8c452d81d7fe547573193d17a3eb6",
    "platform_id": "DB04921",
    "metadata": {
        "name": "Cleviprex 0 5 mg 1mL Emulsion",
        "composition": "0 5 mg 1mL Dirucotide",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of multiple sclerosis MS",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "MS is generally considered an autoimmune disease caused by immune attack against normal components of the central nervous system The specificity of the immune attack at the molecular level is determined in each case by the HLA type of the individual patient and HLA type is known to be one factor that contributes to susceptibility to MS The MBP8298 synthetic peptide is a molecular replicate of the site of attack that is dominant in MS patients with HLA haplotypes DR 2 or DR 4 These HLA types are found in 65 75 of all MS patients",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}